Cargando…

Targeted busulfan and fludarabine-based conditioning for bone marrow transplantation in chronic granulomatous disease

Chronic granulomatous disease (CGD) is a primary immunodeficiency disease caused by impaired phagocytic function. Hematopoietic stem cell transplantation (HSCT) is a definitive cure for CGD; however, the use of HSCT is limited because of associated problems, including transplantation-related mortali...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ju, Hee Young, Kang, Hyoung Jin, Hong, Che Ry, Lee, Ji Won, Kim, Hyery, Song, Sang Hoon, Yu, Kyung-Sang, Jang, In-Jin, Park, June Dong, Park, Kyung Duk, Shin, Hee Young, Kim, Joong-Gon, Ahn, Hyo Seop
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Pediatric Society 2016
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5177714/ https://www.ncbi.nlm.nih.gov/pubmed/28018447 http://dx.doi.org/10.3345/kjp.2016.59.11.S57

Ejemplares similares

Pharmacometabolomics for predicting variable busulfan exposure in paediatric haematopoietic stem cell transplantation patients
por: Kim, Bora, et al.
Publicado: (2017)

Favorable outcomes with durable chimerism after hematopoietic cell transplantation using busulfan and fludarabine-based reduced-intensity conditioning for pediatric patients with hemophagocytic lymphohistiocytosis
por: Suh, Jin Kyung, et al.
Publicado: (2022)

Clinical Characteristics of Pediatric Thalassemia in Korea: A Single Institute Experience
por: Hong, Che Ry, et al.
Publicado: (2013)

Feasibility of Non-TBI Conditioning with Busulfan and Fludarabine for Allogeneic Stem Cell Transplantation in Lymphoid Malignancy
por: Shin, Ho Cheol, et al.
Publicado: (2012)

Chronic graft versus host disease with small bowel obstruction after unrelated hematopoietic stem cell transplantation in a patient with acute myeloid leukemia
por: Yoon, Ju Young, et al.
Publicado: (2012)

Thiotepa-busulfan-fludarabine compared to busulfan-fludarabine for sibling and unrelated donor transplant in acute myeloid leukemia in first remission
por: Saraceni, Francesco, et al.
Publicado: (2017)

Adverse Effects of Busulfan Plus Cyclophosphamide versus Busulfan Plus Fludarabine as Conditioning Regimens for Allogeneic Bone Marrow Transplantation
por: Mehdizadeh, Mahshid, et al.
Publicado: (2021)

Successful Treatment of Primary Central Nervous System Lymphoma without Irradiation in Children: Single Center Experience
por: Yoon, Jong Hyung, et al.
Publicado: (2012)

Association of systolic blood pressure drop with intravenous administration of itraconazole in children with hemato-oncologic disease
por: Lee, Hyeong Jin, et al.
Publicado: (2015)

Extra-cranial Malignant Rhabdoid Tumor in Children: A Single Institute Experience
por: Hong, Che Ry, et al.
Publicado: (2015)

Hemophagocytic lymphohistiocytosis diagnosed by brain biopsy
por: Ju, Hee Young, et al.
Publicado: (2015)

Fludarabine plus reduced-intensity busulfan versus fludarabine plus myeloablative busulfan in patients with non-Hodgkin lymphoma undergoing allogeneic hematopoietic cell transplantation
por: Kamijo, Kimimori, et al.
Publicado: (2023)

Pharmacogenetic Study of Deferasirox, an Iron Chelating Agent
por: Lee, Ji Won, et al.
Publicado: (2013)

Unrelated Bone Marrow Transplantation with a Reduced Toxicity Myeloablative Conditioning Regimen in Wiskott-Aldrich Syndrome
por: Kang, Hyoung Jin, et al.
Publicado: (2008)

Treatment outcomes in children with Burkitt lymphoma and L3 acute lymphoblastic leukemia treated using the lymphoma malignancy B protocol at a single institution
por: Park, Eun Sil, et al.
Publicado: (2011)

Fludarabine-based myeloablative regimen as pretransplant conditioning therapy in adult acute leukemia/myelodysplastic syndrome: comparison with oral or intravenous busulfan with cyclophosphamide
por: Lee, Ji Hyun, et al.
Publicado: (2010)

Successful mobilization using a combination of plerixafor and G-CSF in pediatric patients who failed previous chemomobilization with G-CSF alone and possible complications of the treatment
por: Hong, Kyung Taek, et al.
Publicado: (2012)

Reduced-Intensity Conditioning with Busulfan and Fludarabine for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Lymphoblastic Leukemia
por: Lee, Seung-Shin, et al.
Publicado: (2020)

Conditioning with Fludarabine-Busulfan versus Busulfan-Cyclophosphamide Is Associated with Lower aGVHD and Higher Survival but More Extensive and Long Standing Bone Marrow Damage
por: He, Xin, et al.
Publicado: (2016)

Outcome of Reinduction Chemotherapy with a Modified Dose of Idarubicin for Children with Marrow-Relapsed Acute Lymphoblastic Leukemia: Results of the Childhood Acute Lymphoblastic Leukemia (CALL)-0603 Study
por: Koh, Kyung-Nam, et al.
Publicado: (2017)

Double umbilical cord blood transplantation for children and adolescents
por: Kang, Hyoung Jin, et al.
Publicado: (2010)

Does anti-thymocyte globulin have a place in busulfan/fludarabine conditioning for matched related donor hematopoietic stem cell transplantation?
por: Ji, Young Sok, et al.
Publicado: (2016)

Production of germline chimeric quails following spermatogonial cell transplantation in busulfan-treated testis
por: Kim, Young Min, et al.
Publicado: (2018)

Pharmacogenetic Analysis of Pediatric Patients with Acute Lymphoblastic Leukemia: A Possible Association between Survival Rate and ITPA Polymorphism
por: Kim, Hyery, et al.
Publicado: (2012)

In vivo enrichment of busulfan-resistant germ cells for efficient production of transgenic avian models
por: Kim, Young Min, et al.
Publicado: (2021)

High Transcript Level of FLT3 Associated with High Risk of Relapse in Pediatric Acute Myeloid Leukemia
por: Kang, Hyoung Jin, et al.
Publicado: (2010)

Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active
por: Garcia, Jacqueline S., et al.
Publicado: (2021)

What is the minimum adequate busulfan dose for patients with sickle cell disease undergoing reduced intensity conditioning with fludarabine, busulfan, and anti‐thymocyte globulin?
por: AlJohani, Naif I., et al.
Publicado: (2021)

Allogeneic stem cell transplant for multiple myeloma & myelofibrosis with split-dose busulfan, fludarabine & cyclophosphamide
por: Trunk, Andrew D., et al.
Publicado: (2023)

Quantification of Human Plasma-Busulfan Concentration by Liquid Chromatography-Tandem Mass Spectrometry
por: Moon, Soo Young, et al.
Publicado: (2014)

Quantification of Thiopurine Nucleotides in Erythrocytes and Clinical Application to Pediatric Acute Lymphoblastic Leukemia
por: Moon, Soo Young, et al.
Publicado: (2019)

ALK Protein Expression Is Related to Neuroblastoma Aggressiveness But Is Not Independent Prognostic Factor
por: Lee, Ji Won, et al.
Publicado: (2018)

Clofarabine-fludarabine-busulfan in HCT for pediatric leukemia: an effective, low toxicity, TBI-free conditioning regimen
por: Versluijs, A. Birgitta, et al.
Publicado: (2022)

APEX1 Polymorphism and Mercaptopurine-Related Early Onset Neutropenia in Pediatric Acute Lymphoblastic Leukemia
por: Kim, Hyery, et al.
Publicado: (2018)

Fludarabine with pharmacokinetically-guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients
por: Andersson, Borje S., et al.
Publicado: (2016)

Clinical Outcome of Relapsed or Refractory Burkitt Lymphoma and Mature B-Cell Lymphoblastic Leukemia in Children and Adolescents
por: Kim, Hyery, et al.
Publicado: (2014)

Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)
por: Saraceni, Francesco, et al.
Publicado: (2019)

Retrospective Analysis of Peripheral Blood Stem Cell Transplantation for the Treatment of High-Risk Neuroblastoma
por: Kim, Eun Kyung, et al.
Publicado: (2007)

Leukemia cell mobilization with G-CSF plus plerixafor during busulfan-fludarabine conditioning in allogeneic stem cell transplantation
por: Konopleva, Marina, et al.
Publicado: (2015)

Prospective validation of a novel dosing scheme for intravenous busulfan in adult patients undergoing hematopoietic stem cell transplantation
por: Cho, Sang-Heon, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_8i67ocpp0amnlh2u8vsmg3jodi